[
  {
    "ts": "2026-02-21T13:00:00+00:00",
    "headline": "TREMFYA速 (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years",
    "summary": "Johnson & Johnson (NYSE: JNJ) today announced new long-term data from the QUASAR long-term extension (LTE) study showing that TREMFYA速 (guselkumab) sustained clinical, endoscopic, and histologic outcomes through Week 140 in adults with moderately to severely active ulcerative colitis (UC). These data are among the 30 company-sponsored abstracts being presented at the European Crohn's and Colitis Organisation (ECCO) 2026 conference.",
    "url": "https://finance.yahoo.com/news/tremfya-guselkumab-long-term-data-130000357.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "e8d9a2fe-7d12-318c-87fc-b4e04c695041",
      "content": {
        "id": "e8d9a2fe-7d12-318c-87fc-b4e04c695041",
        "contentType": "STORY",
        "title": "TREMFYA速 (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years",
        "description": "",
        "summary": "Johnson & Johnson (NYSE: JNJ) today announced new long-term data from the QUASAR long-term extension (LTE) study showing that TREMFYA速 (guselkumab) sustained clinical, endoscopic, and histologic outcomes through Week 140 in adults with moderately to severely active ulcerative colitis (UC). These data are among the 30 company-sponsored abstracts being presented at the European Crohn's and Colitis Organisation (ECCO) 2026 conference.",
        "pubDate": "2026-02-21T13:00:00Z",
        "displayTime": "2026-02-21T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/f6c13e47c55b1b30082ae2cdc7f55cf9",
          "originalWidth": 400,
          "originalHeight": 37,
          "caption": "(PRNewsfoto/Johnson & Johnson)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/quTqSNgiT7fKbCGSKfppRg--~B/aD0zNzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/f6c13e47c55b1b30082ae2cdc7f55cf9.cf.webp",
              "width": 400,
              "height": 37,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FHkqospZrsXFMabwu_MWUQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f6c13e47c55b1b30082ae2cdc7f55cf9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/tremfya-guselkumab-long-term-data-130000357.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/tremfya-guselkumab-long-term-data-130000357.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]